Advertisement

Rheumaderm pp 319-325 | Cite as

NSAIDs/Corticosteroids—Primum Non Nocere

  • J. Dequeker
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 455)

Abstract

NSAIDs/Corticosteroids are the most used and maybe misused drugs against “aches and pains of the musculoskeletal system”. Their effectiveness to reduce (not cure) inflammation and related pain is without doubt. The problem is that of their side effects in particular of the GI-tract and other body systems. It is clear that these side effects occur more often and more seriously in a number of patients, the so-called high risk group: elderly women, patients with previous history of gastro-intestinal ulcer and corticosteroid users.

The discovery that there are two pathways to influence cyclooxygenase activity and prostaglandin production and that some NSAIDs have a more marked COX-2 and COX-1 inhibition opens new perspectives. COX-1 is present in normal tissues and is responsible for the production of protective prostaglandins in the gastric mucosa and other tissues. COX-2 is induced by inflammatory cytokines and plays a role in the inflammatory cascade. Therefore more specific COX-2 antagonists should be safer for the gastro-intestinal mucosa and kidney function.

The risk of hip fracture is 50% higher in patients receiving long-term corticosteroid therapy, and 30–35% of corticosteroid patients have vertebral fractures. The renewed interest in osteoporosis and increased number of papers on bone loss in RA reflect on the one hand the advances in technology to measure bone mineral density (BMD) accurately and precisely, and on the other hand the availability of effective drugs to stop bone loss and reverse the process.

The possible deleterious effect of low dose corticosteroids continues to be a subject of concern, particularly in rheumatology where serum levels of free cortisone may be higher because of low albumen and other protein changes. Recently, several editorials and conflicting data obtained from cross-sectional and longitudinal studies in RA on steroid- induced osteoporosis have been published.

Because the pathogenesis of steroid osteoporosis is distinct from that of entities such as postmenopausal osteoporosis, each therapy requires specific assessment in steroid treated patients. In recent years a wide variety of therapies, for example hormone replacement therapy, calcium supplements administered with vitamin D metabolites, thiazides, diuretics, anabolic steroids, tibolone, calcitonin and bisphosphonates, have been proposed to prevent osteoporosis in patients receiving longterm corticosteroid therapy, but there have been few carefully controlled trials, except for vitamin D and bisphosphonates.

Keywords

Measure Bone Mineral Density Anabolic Steroid Bone Turnover Status Steroid Treated Patient Protective Prostaglandin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Emery P. Selective COX-2 inhibition: relevance in arthritis. Curr Opin Rheumatol;8(suppl 1):S21–4. 1996CrossRefGoogle Scholar
  2. 2.
    Fries J. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol;18:6–10. 1991Google Scholar
  3. 3.
    Fries J, Miller SR, Spitz PW, et al. Toward and epidemiology of gastropathy associated with non-steroidal anti-inflammatory drugs use. Gastroenterol;96:647–55. 1989Google Scholar
  4. 4.
    Myllykangas-Luosujarvi R, Aho K, Isomäki H. Death attributed to antirheumatic medication in a nationwide series of 1666 patients with rheumatoid arthritis who have died. J Rheumatol;22:2214–7. 1995PubMedGoogle Scholar
  5. 5.
    Collier D St J, Pain JA. Anti-inflammatory drugs and upper gastrointestinal perforation. In: Rainsford KD, Velo GP, eds. Side effects of anti-inflammatory drugs, part 1: clinical and epidemiological aspects. Lancaster: MTP Press:285–93. 1986Google Scholar
  6. 6.
    Garcia Rodrίguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet;343:369–72. 1994Google Scholar
  7. 7.
    DiMario F, Leandro G, Battaglia G, et al. Do concomitant diseases and therapies affect the persistence of ulcer symptoms in the elderly? Dig Dis Sci;41:17–21. 1996CrossRefGoogle Scholar
  8. 8.
    Sergent JS. Yearbook of Rheumatology, London: Mosby,1997.Google Scholar
  9. 9.
    Henry D, Lim LL-Y, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br J Med; 312:1563–6. 1996CrossRefGoogle Scholar
  10. 10.
    Singh G, Ramey DR, Morfeld D, Shi H, Hatoum HT, Fries JF. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Int Med; 156:1530–6. 1996CrossRefGoogle Scholar
  11. 11.
    Masferrer JL, Seibert K, Zweifel B, Needleman P. Endogenous glucocorticoids regulate an inducible cyclo-oxygenase enzyme. Proc Natl Acad Sci USA;89:3917–21.1992Google Scholar
  12. 12.
    Vane JR. Towards a better aspirin. Nature;361:2\5–6. 1994Google Scholar
  13. 13.
    Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and non ulcerogenic. Proc Natl Acad Sci USA;91:3228–32. 1994PubMedCrossRefGoogle Scholar
  14. 14.
    Dequeker J. Does it make a difference? Experience with COX-2 inhibition in 10,000 osteoarthritis patients. In press.Google Scholar
  15. 15.
    Dequeker J, Westhovens R. Low dose corticosteroids associated osteoporosis in rheumatoid arthritis and its prophylaxis and treatment: bones of contention. J Rheumatol;22:1013–9. 1995PubMedGoogle Scholar
  16. 16.
    Spector TD, Sambrook PN. Steroid osteoporosis. A pragmatic approach is needed while prospective trials are awaited. BMJ;301:519–20. 1993CrossRefGoogle Scholar
  17. 17.
    Sambrook PN, Jones G. Corticosteroid osteoporosis. Br J Rheumatol;34:8–12. 1995PubMedCrossRefGoogle Scholar
  18. 18.
    Reid IR. Steroid osteoporosis. Calcif Tissue Int;45:63–7. 1989PubMedCrossRefGoogle Scholar
  19. 19.
    Meunier PJ. Is steroid-induced osteoporosis preventable? N Engl J Med;328:1781–2.1993Google Scholar
  20. 20.
    Dequeker J, Geusens P. Osteoporosis and arthritis. Ann Rheum Dis;49:276–80. 1990PubMedCrossRefGoogle Scholar
  21. 21.
    Chesnut CH. Osteoporosis and its treatment. New Engl J Med;326:406–8. 1992PubMedCrossRefGoogle Scholar
  22. 22.
    Peat ID, Healy S, Reid DM, Ralston SH. Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis;54:66–8. 1995PubMedCrossRefGoogle Scholar
  23. 23.
    Cooper C. Osteoporosis in rheumatological practice: questions to be answered. Ann Rheum Dis;54:1–2. 1995PubMedCrossRefGoogle Scholar
  24. 24.
    Geusens P, Dequeker J. Locomotor side-effects of corticosteroids. Baillières Clin Rheumatol;5:99–118. 1991PubMedCrossRefGoogle Scholar
  25. 25.
    Dequeker J. Kortikoide, Knochenmasse und Frakturen bei rheumatischen Erkrankungen. Aktuelle Rheumatologie 18:14–8. 1993CrossRefGoogle Scholar
  26. 26.
    MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med; 104:648–51. 1986PubMedGoogle Scholar
  27. 27.
    Olgaard K, Storm T, Wowern NV, et al. Glucocorticoid-induced osteoporosis in the lumbar spine, forearm, and mandible of nephrotic patients: a double-blind study on the high-dose long-term effects of prednisone versus deflazacort. Calcif Tissue Int;50:490–7. 1992PubMedCrossRefGoogle Scholar
  28. 28.
    Messina OD, Barreira JC, Zanchetta JR, et al. Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis. J Rheumatol; 19:1520–6. 1992PubMedGoogle Scholar
  29. 29.
    Blumsohn A, Herrington K, Hannon RA, Shao P, Eyre DR, Eastell R. The effect of calcium supplementation on the circadian rhythm of bone resorption. J Clin Endocrinol Metab;79:130–5. 1994CrossRefGoogle Scholar
  30. 30.
    van de Voorde M, Dequeker J, Geusens R Effect of one late evening dose of calcium on bone resorption in postmenopausal women. In: Christiansen C, Overgaard K, eds. Osteoporosis 1990. Copenhagen: Osteopress ApS: 1192–3. 1990Google Scholar
  31. 31.
    Reid IR, Ibbertson HK. Calcium supplements in the prevention of steroid-induced osteoporosis. Am J Clin Nutr,44:287–90. 1986PubMedGoogle Scholar
  32. 32.
    Bijlsma JWJ, Raymakers JA, Mosch C, et al. Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia. Clin Exp Rheumatol;6:113–9. 1988PubMedGoogle Scholar
  33. 33.
    Adams JS, Wahl TO, Lukert BR Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism;30:217–21. 1981PubMedCrossRefGoogle Scholar
  34. 34.
    Van Cleemput J, Daenen W, Geusens P, Dequeker J, Van de Werf F, Vanhaecke J. Prevention of bone loss in cardiac transplant recipients. A comparison of bisphosphonates and vitamin D. Transplantation;61: 1495–9. 1996PubMedCrossRefGoogle Scholar
  35. 35.
    Garcia-Delgado I, Prieto S, Gil-Fraguas L, Robles E, Rufilanchas JJ, Hawkins F. Calcitonin, Etidronate, and Calcidiol treatment in bone loss after cardiac transplantation. Calcif Tissue Int 60:155–9. 1997PubMedCrossRefGoogle Scholar
  36. 36.
    Boutsen Y, Jamart J, Esselinckx W, Stoffel M, Devogelaer JP. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif Tissue Int 61:266–71. 1997PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • J. Dequeker
    • 1
  1. 1.Division of RheumatologyUniversity of LeuvenBelgium

Personalised recommendations